Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta2-spectrin small interfering rna
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Typically Transfection Or Injection (intracellular Delivery); Not Established For Clinical Use
01
Overview
Beta2-spectrin small interfering RNA is an experimental RNA therapy designed to selectively inhibit the expression of beta2-spectrin (gene SPTBN1), a critical adaptor protein in the TGF-β/Smad signaling pathway involved in cell differentiation, DNA repair, and tumor suppression, particularly in hepatocellular carcinoma. By targeting beta2-spectrin mRNA, siRNA suppresses beta2-spectrin expression to study its role in various cellular processes and disease models, including liver cancer, cell cycle regulation, DNA damage repair, and membrane organization. Delivery of siRNA against beta2-spectrin upregulates cancer stem cell markers and dysregulates differentiation, whereas restoring beta2-spectrin suppresses malignant phenotypes[1][3][5].
- Other names
- SPTBN1 siRNASPTBN-1 siRNASPTBN 1 siRNA
02
Targets
SPTBN1 (Spectrin beta chain, non-erythrocytic 1)
Beyond the preview
Go deeper on beta2-spectrin small interfering rna.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta2-spectrin small interfering rna.